Drug trial targets Body's Self-Attacking immune cells
NCT ID NCT01842386
Summary
This study tested whether a drug called rituximab could safely treat rare diseases where the immune system mistakenly attacks the body's own proteins. Seven adults with these conditions, who were not helped by standard treatments, received rituximab infusions over six months. The main goal was to check if the treatment was safe and tolerable for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.